Although Toll-like receptors (TLRs) have been implicated in the regulation of stem cell functions, their role in osteogenic differentiation of adipose-derived stromal cells (ASCs) has not been reported. We found that ASCs express a restricted subset of TLRs, including TLR1-TLR5, and that TLR agonists such as Pam3CSK4 (TLR1/2 agonist), polyinosinic:polycytidylic acid (TLR3 agonist), lipopolysaccharide (TLR4 agonist), and flagellin (TLR5 agonist), but not R848 (TLR7/8 agonist), consistently induced osteogenic differentiation in murine-derived ASCs, which coincided with the TLR expression pattern of ASCs. Cytokine expression profiles induced by TLR agonists and results from subsequent functional assays indicated that interleukin-6 (IL-6) together with soluble IL-6 receptor (sIL-6R) enhanced osteogenic differentiation of ASCs by activating STAT3. Small interfering RNA (siRNA)mediated STAT3-silencing blunted osteogenesis and the expression of osteogenic markers, whereas STAT3 overexpression resulted in an increase in osteogenesis. Consistently, STAT3 inhibitor treatment reduced osteogenesis, STAT3 phosphorylation, and expression of osteogenic markers including osterix. Chromatin immunoprecipitation (ChIP) assays indicated that STAT3 binding to the STAT3-binding sites on the osterix promoter increased during IL-6-stimulated osteogenesis. Our results thus establish TLRs as novel regulators of ASCs which signal through IL-6/STAT3 pathway and induce osterix expression as a part of the osteogenesis.
Introduction
Toll-like receptors (TLRs) are a family of pattern recognition receptors that sense pathogen-associated molecular patterns of microbial pathogens [1] . Ten human and 12 murine TLRs have been characterized such as TLR1-TLR10 in humans, and TLR1-TLR9, TLR11, TLR12 and TLR13 in mice. The murine TLR10 homolog is believed to be a pseudogene. TLR2 is essential for the recognition of lipoproteins and lipoteichoic acids in Gram-positive bacteria. TLR3 is implicated in virus-derived double-stranded RNA. TLR4 is predominantly activated by lipopolysaccharide (LPS). TLR5 detects bacterial flagellin, and TLR9 is required for the response to unmethylated CpG DNA [2] [3] [4] [5] . Finally, TLR7 and TLR8 recognize small synthetic antiviral molecules [6] , and single-stranded RNA is their natural ligand [7] . Although TLRs have been extensively studied in the early innate immune response to invading pathogens by sensing microorganisms [8, 9] , TLRs and their ligands also regulate functions of mesenchymal stem cells (MSCs) [10, 11] . Specifically, Pevsner-Fischer et al. [12] found that TLRs serve as regulators of MSC proliferation and differentiation and might affect the maintenance of MSC multipotency. However, the molecular mechanisms involved in the differentiation of MSCs by TLR ligand stimulation remain to be further investigated.
Interleukin-6 (IL-6) is a pleiotropic cytokine that regulates immune responses, acute phase reactions, and hematopoiesis and may play a central role in host defense mechanisms [13] . IL-6 is usually not produced constitutively by normal cells, but its expression is readily induced by a variety of cytokines, LPS, or viral infections in a variety of cells [14, 15] . IL-6 binds to its membrane-bound receptor (IL-6R) or its soluble receptor (sIL-6R). The complex of IL-6/IL-6R (or IL-6/sIL-6R) interacts with the gp130 protein, which dimerizes and initiates downstream signaling [16] . Thus, either the membrane-bound or the soluble IL-6R mediates the IL-6 signal in cells, as virtually all cells in the body express gp130 [17] . IL-6 signaling triggers activation of the gp130-associated Janus kinase pathway [18] . This leads to activation of STAT3 by tyrosine phosphorylation and then to STAT3 dimerization [19] . Dimerized STAT3 is subsequently translocated to the nucleus where it binds to specific DNA sites as homo or heterodimers to stimulate transcription of response genes [20] . 
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Biochimica et Biophysica Acta MSCs are adult stem cells that reside in various types of organs and tissues, including bone marrow, adipose tissue and muscle [21] , and differentiate into several lineages such as osteoblasts, chondrocytes, or adipocytes [22] . In addition to the multilineage differentiation capacity that is useful for tissue regeneration, MSCs have immunomodulatory activity [23] . MSCs inhibit T cell activation, dendritic cell differentiation, and B cell proliferation and impair the cytolytic potential of natural killer cells in vitro [24] . Immunosuppression after MSC infusion in vivo has also been documented in diverse animal models of disease [25] . These effects are partially explained by the ability of MSCs to secrete a vast array of soluble mediators, some of which have immunomodulatory properties such as IL-10, prostaglandin E2, or nitric oxide [21] . However, regulation of MSC lineage commitment by immunomodulatory molecules such as TLR ligands or cytokines has not been well-defined.
Here, we show that some TLR agonists are capable of utilizing innate immune receptor TLRs to induce IL-6 expression in ASCs. Importantly, IL-6 signaling appears to be required to induce osterix, which is an essential transcriptional factor for osteogenic differentiation. Our data indicate a previously unappreciated molecular link between the innate immune system and osteogenesis, and suggest that the TLR/IL-6 signaling pathway may be useful for modulating osteogenic differentiation of ASCs.
Materials and methods

Reagents
Synthetic triacylated lipoprotein Pam3CSK4, Salmonella Typhimurium Flagellin, and R848 were purchased from InvivoGen (San Diego, CA). Synthetic, double-stranded RNA analogue, polyinosinic:polycytidylic acid (poly-IC), Escherichia coli 055:B5 LPS, and JSI-124 (Cucurbitacin I hydrate) were purchased from Sigma (St. Louis, MO). Human recombinant IL-6 and sIL-6R were purchased from PeproTech (New Jersey, USA).
ASC isolation and culture
ASCs were obtained from 6-to 8-week-old male C57BL/6 mice (The Jackson Laboratory) as described previously [26] . In brief, adipose tissue dissected from a subcutaneous anterior abdominal wall and cut into fine pieces, was digested with 0.075% collagenase IA (Sigma) for 1 h at 37°C with vigorous shaking. The released cells were centrifuged at 300 ×g for 10 min and the cell pellet, suspended with PBS, was filtered through a 100 μm cell strainer (BD Biosciences, San Jose, CA) to remove tissue debris. Then, collagenase was removed by dilution with PBS and centrifuged twice at 300 ×g for 10 min. The cell pellet was suspended in 0.83% NH 4 Cl and incubated to remove contaminating red blood cells. The residual cells were washed and centrifuged twice with PBS and cultured in Dulbecco's modified Eagle's medium (DMEM; HyClone, Logan, UT) supplemented with 10% FBS (HyClone), 100 units/ml penicillin, and 100 μg/ml streptomycin (HyClone) in tissue cultured dishes at 37°C in a 5% CO 2 humidified incubator. After 4 h, non-adherent cells were removed by 2 to 3 washes with PBS; adherent cells were cultured further in complete medium until the cells reached 80 to 90% confluence. The adherent cells were analyzed for immunophenotypic features. ASCs from passage 3 to passage 5 were used in all experiments described.
Induction of differentiation
The potential of the isolated cells to differentiate into osteogenic and adipogenic lineages was examined as described previously [27] . For osteogenesis, cells were allowed to grow to 70% to 90% confluence and then cultured in osteogenic medium containing 10 mM β-glycerol phosphate (Sigma), 50 μg/ml ascorbate-2-phosphate (Sigma), 10 −7 M dexamethasone (Sigma) and 25 ng/ml human recombinant bone morphogenetic protein 2 (BMP-2, R&D Systems). The culture medium was changed 3 times per week for 1 to 2 wk, respectively. The degree of extracellular matrix calcification was estimated using Alizarin Red S (2% ARS, pH 4; Alphachem, Middlesex, UK) staining and von Kossa (1% silver nitrate solution; Sigma) staining. Alkaline phosphatase (ALP) activity was detected by BCIP/NBT color development substrate (Promega, Wisconsin, USA) according to the manufacturer's instructions. For adipogenesis, cells were allowed to grow to 70 to 90% confluence and then cultured in adipogenic medium containing 50 μg/ml indomethacin (Sigma), 10 −7 M dexamethasone (Sigma), 5 μg/ml insulin (Sigma) and 10 μM rosiglitazone (Alexis). The culture medium was changed 3 times per week for 1 to 2 wk and assessed by the use of an oil red O staining as an indicator of intracellular lipid accumulation. For oil red O quantification, 4% IGEPAL CA 630 (Sigma) in isopropanol was added to each well. Light absorbance by the extracted dye was measured in 492 nm.
Cytokines ELISA
ASCs were seeded in 96-well plates and, on the next day, were replaced to either control medium or medium containing various TLR agonists. Conditioned medium were collected following treatment for 6 h or 24 h and cytokine concentration was determined by ELISA for IL-6, IL-1β, IL-10, IL-12(p40), and TNF (OptEIA kit; BD Pharmingen, San Diego, CA) according to the manufacturer's instructions. Results were calculated from a standard curve.
Evaluation of cell proliferation
To confirm proliferative effects in TLR agonist treated ASCs, BrdU cell proliferation kit (Roche Applied Science) was used. Cells were seeded in a 96-well plate and incubated overnight to allow the cells to adhere to the plate. The cells were treated with various TLR agonists for 24 h, respectively. Each sample was assayed in triplicate. After that, BrdU was added and the cells were reincubated for 4 h. After removing the culture medium, cells were fixed and the DNA denatured. Then, peroxidase-conjugated anti-BrdU was added to bind to the BrdU. The immune complexes were detected by the 3,3′,5,5′ tetramethylbenzidine substrate reaction, and the resultant color was read at 370 nm in a microplate spectrophotometer. The absorbance values correlated directly to the amount of DNA synthesis and thereby to the number of proliferating cells in culture.
Reverse transcription PCR and real time PCR
Total RNAs were isolated from ASCs using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. After denaturation of total RNA at 70°C for 10 min, first-strand cDNA was synthesized with oligo(dT) primers and MMLV-reverse transcriptase (SolGent, Seoul, Korea). PCR amplifications were performed using the specific primers. Primer sequences are shown in Supplementary  Table 1 . PCR products were separated by agarose gel electrophoresis and stained with ethidium bromide. The expression levels of each sample were normalized against glyceraldehyde 3 phosphate dehydrogenase (GAPDH) mRNA expression. The relative mRNA levels of osterix, ALP, and osteopontin were evaluated by real time PCR using SYBR Green Master kit (Kapa Biosystems, Woburn, MA). Gene specific primer sequences are shown in Supplementary Table 1 . Reactions were performed in triplicate on ABI PRISM 7300 unit (Applied Biosystems). The relative expression levels were calculated using the comparative C T method (ΔΔC T ) and values were normalized to actin level as an internal control gene. Melting curve analysis was included to assure that only one PCR product was formed.
Western blot analysis
Cells were lysed in cell lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% sodium deoxycholate, 1% Nonidet P-40, 1 mM EDTA, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 1 μg/ml of leupeptin, aprotinin, and pepstatin A, 1 mM sodium orthovanadate and 1 mM NaF for 20 min on ice. The lysates were centrifuged at 14,000 ×g for 20 min at 4°C. The supernatants were boiled in SDS sample buffer containing 0.5 M β-mercaptoethanol. Protein concentration was determined by the Bradford assay (Bio-Rad). Equal amounts of proteins were separated by 10% SDS-PAGE and electrotransferred to a nitrocellulose membrane (Millipore, Billerica, MA, USA). The membrane was blocked in PBS containing 5% nonfat dry milk for 1 h and then immunoblotted overnight at 4°C on a shaker with antibodies to phospho-Tyr 705 -STAT3, STAT3 (Cell Signaling Technology, Danvers, MA), osterix (Abcam, Cambridge, MA, USA), and GAPDH (AbFrontier, Seoul, Korea) in Tris-buffered saline containing 0.05% Tween 20 (TBS-T) with 1% bovine serum albumin (BSA). Following 2 washes in TBS-T, the membrane was incubated with either horseradish peroxidase-conjugated anti-rabbit antibody or antimouse antibody (Thermo Scientific) in TBS-T for 1 h at room temperature. Proteins were detected using an ECL detection kit (Amersham Biosciences, NJ, USA).
Immunofluorescence assay
Serum-deprived ASCs grown on cover glass were treated with either control medium (medium only) or containing 50 ng/ml IL-6 and 50 ng/ml sIL-6R for 1 h. Cells were washed in PBS and fixed in 4% paraformaldehyde for 10 min and permeabilized with 0.1% Triton X-100 for 20 min at RT. Cells were incubated in 5% BSA for 30 min at RT and then incubated with anti-STAT3 (Cell Signaling Technology, Danvers, MA) monoclonal antibody for 2 h at RT. After being washed three times in PBS, cells were further incubated with Alexa Fluor Red-conjugated goat anti-mouse IgG (Molecular Probes, Invitrogen, CA) for 1 h at RT. Cells were washed again twice in PBS prior to 4′,6-diamidino-2-phenylindole (DAPI) staining and mounting. Images were analyzed using the LSM 510 META laser confocal microscopy system (Carl Zeiss Microimaging Inc., Thornwood, NY, USA).
Small interfering RNA (siRNA) transfection
Double-stranded, siRNAs (19-mer) targeting mouse STAT3 were synthesized by Integrated DNA Technologies, Inc. (IDT; Coralville, IA). The corresponding target mRNA sequences for the siRNAs were as follows: si-STAT3, CAGCACAACCUUCGAAGAA; scrambled nontargeting siRNA, ACGTGACACGTTCGGAGAA, as a negative control. ASCs were transfected with the gene-specific siRNA at a concentration of 10 nM using Lipofectamine™ RNAiMAX (Invitrogen) according to the manufacturer's protocol.
Retroviral transduction
Retroviral vector encoding STAT3 was obtained from Addgene (pMXs-STAT3C, Addgene plasmid 13373, Cambridge, MA, USA). The plasmids were transfected into Plat-E cells, as described previously [28] , and the supernatant was collected 24 to 36 h after transfection. The pMXs-puro vector and Plat-E cells were kindly provided by T. Kitamura (University of Tokyo, Japan). The packaged retroviral particles in the supernatant were filtered through 0.45 μm filters (BD Biosciences), supplemented with polybrene (10 μg/ml; Sigma) then used to infect ASCs that had been seeded 24 h before infection. After 24 h, 1 μg/ml puromycin was added to the medium to select for infected cells for 2 d. Puromycin-resistant cells were used in all experiments described.
Transfection and luciferase reporter assay
The pGL3-Osx reporter plasmid [29] containing mouse osterix promoter from − 2965 to + 80 relative to the transcription start site was kindly provided by Subburaman Mohan (Loma Linda University, USA). ASCs were transfected with reporter constructs via electroporation using the Neon Transfection System (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Briefly, ASCs were treated with a single pulse of 1100 V for 30 ms, in a 100 μl electroporation tip. On the next day, cells were cultured with or without 50 ng/ml IL-6 and 50 ng/ml sIL-6R for 3 d. Luciferase activity was measured by the luciferase assay system (Promega) and normalized to the activity of the control (pRenilla). The data were obtained from 3 independent transfections and presented as the -fold induction in luciferase activity (mean ± S.D.) relative to the control.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were done using EZ-ChIP kit (Millipore, Bedford, MA) as per manufacturer's instructions. In brief, 1 × 10 6 cells were treated with either control medium (osteogenic differentiation medium) or containing 50 ng/ml IL-6 and 50 ng/ml sIL-6R for 1 h. Then, formaldehyde was added at a final concentration of 1% directly to cell culture medium for 10 min followed by a treatment with 125 mM glycine. Cells were washed twice using cold PBS, resuspended in 500 μl of SDS lysis buffer containing protease inhibitors (1 mM PMSF, 1 μg/ml leupeptin, aprotinin, and pepstatin A) and incubated for 10 min on ice. Lysates were sonicated and cleared by centrifugation, and sonicated chromatin was diluted in ChIP dilution buffer adding protease inhibitors as above. There was 1% of the diluted cell supernatant with no primary antibody saved as total input chromatin. The chromatin solution was precleared with the addition of salmon sperm DNA/protein A agarose (50% slurry) for 1 h at 4°C, then precleared chromatin was incubated with STAT3 and mouse IgG for control overnight at 4°C with rotation. Immunoprecipitated complexes were collected by adding salmon sperm DNA/protein A agarose for 1 h at 4°C with rotation. Following washing of the beads, the histone complexes were eluted twice from the antibody. Eluates were added 10 μl of 5 M NaCl and reversed the cross-links at 65°C for 4 h, and DNA was purified and recovered. PCR amplifications were performed using with primers that detect sequences located in the osterix promoter; 5′-TGACAGCCACCTGGTTCCAATACT-3′ (sense) and 5′-GGGAGAAGAGTACCCACTTTCTTG-3′ (antisense). PCR products were separated by agarose gel electrophoresis and stained with ethidium bromide.
Statistical analysis
The data are presented as mean ± S.D. The Student's t-test was used for statistical analysis. p b 0.05 was considered statistically significant.
Results
TLR agonists induce osteogenic differentiation of ASCs
To examine the role of TLRs in the osteogenic and adipogenic differentiation of ASCs, we first determined the TLR expression from total RNA in murine ASCs. As a positive control, the murine monocyte/macrophage RAW264.7 cell line expressed all TLRs tested (TLR1-TLR9). In contrast, ASCs expressed a restricted TLR pattern featured with the transcription of TLR1-TLR5 (Fig. 1A) . Next, we examined the effect of TLR agonists on osteogenic and adipogenic differentiation. As shown in Supplementary Fig. 1 , Pam3CSK4 (TLR1/2 agonist), poly-IC (TLR3 agonist), and LPS (TLR4 agonist) reduced the intracellular lipid accumulation. Interestingly, Pam3CSK4, poly-IC, LPS, and flagellin (TLR5 agonist) significantly induced calcium deposition in a dose-dependent manner, whereas R848 (TLR7/8 agonist) had no effect (Fig. 1B) . Notably, ASCs did not express TLR7/8. Moreover, TLR agonists had no effect on ASC proliferation ( Supplementary Fig. 2) . These results suggest that TLR agonists induced differentiation of ASCs into osteoblasts but not into adipocytes.
TLR agonists induce IL-6
Because activating TLRs can influence cytokine secretion, we tested the effect of TLR agonists on the production of cytokines by enzymelinked immunosorbent assay. Upon stimulation, the patterns of cytokine expression and the magnitude of their expression varied depending on the TLR agonist. Pam3CSK4, poly-IC, LPS, and flagellin did not induce secretion of pro-inflammatory cytokines including IL-1β or tumor necrosis factor (TNF). LPS increased IL-10 and IL-12(p40), whereas Pam3CSK4, poly-IC, and flagellin did not ( Supplementary Fig. 3 ). Most importantly, Pam3CSK4, poly-IC, LPS, and flagellin significantly increased IL-6 secretion depending on dose and time, but R848 and CpG (TLR9 agonist) had less of an effect (Fig. 2 ).
IL-6 enhances osteogenic differentiation of ASCs
Considering TLR expression and IL-6 secretion in ASCs, it is possible that IL-6 might be involved in TLR-mediated osteogenic differentiation. However, treatment of ASCs with IL-6 alone did not cause any changes in Alizarin Red S staining ( Supplementary Fig. 4A ). Because expression of the membrane-bound form of IL-6R was not detected in ASCs by RT-PCR ( Supplementary Fig. 4B ), ASCs were incubated in osteogenic medium containing IL-6 and sIL-6R for 2 wk. As shown in Fig. 3A , ALP activity (upper) and Alizarin Red S (middle) and von Kossa (lower) staining showed that exogenously adding IL-6/sIL-6R stimulated osteogenic differentiation in a dose-dependent manner. IL-6/sIL-6R consistently increased mRNA levels of osterix, ALP, and osteopontin ( Fig. 3B ). Interestingly, protein levels of the osterix transcription factor essential for osteogenesis [30] were increased markedly by IL-6/sIL-6R (Fig. 3C) . These results suggest that the IL-6/ sIL-6R complex, but not IL-6 alone, plays a role in ASC osteogenesis.
TLR agonists activate STAT3 in ASCs
IL-6 induces nuclear translocation of STAT3 from the cytosol, which results in STAT3-dependent gene expression. We investigated whether stimulation with IL-6/sIL-6R activates STAT3 in ASCs. As shown in Fig. 4A , IL-6/sIL-6R caused a rapid (within 5 min) and long lasting increase in STAT3 phosphorylation levels. Furthermore, STAT3 translocated to the nucleus upon stimulation (Fig. 4B) . To examine whether TLR agonists induce STAT3 phosphorylation, ASCs were incubated with osteogenic medium in the presence of the TLR Fig. 3 . IL-6/sIL-6R enhances osteogenic differentiation of ASCs. (A) ASCs were incubated with osteogenic differentiation medium with or without the indicated concentrations of IL-6 and sIL-6R. After 2 wk, ALP activity was determined by staining with NBT/BCIP staining (upper) and cellular mineralization was assessed by Alizarin Red S (middle) and von Kossa (lower) staining. (B) ASCs were incubated with osteogenic differentiation medium containing IL-6 (100 ng/ml) and sIL-6R (100 ng/ml) for 2 wk. Total RNAs were isolated from cultured ASCs to determine mRNA levels of osterix, ALP, and osteopontin by real time PCR analysis. Results represent means ± S.D. *p b 0.01, **p b 0.001, significantly different from IL-6 untreated control. (C) As in (A), except that total protein was isolated from cells to detect osterix expression by immunoblot analysis. GAPDH was used as the internal loading control. Results are representative of at least three independent experiments. Fig. 4 . IL-6/sIL-6R and TLR agonists activate STAT3 in ASCs. (A) ASCs were treated with or without IL-6 (50 ng/ml) and sIL-6R (50 ng/ml) for 5 min to 4 h, and cell lysates were immunoblotted with phospho-Tyr 705 -STAT3 antibody. Membranes were reblotted with GAPDH antibody to ensure equal protein loading. (B) ASCs were treated with or without IL-6 (50 ng/ml) and sIL-6R (50 ng/ml) for 1 h to induce nuclear translocation of STAT3. Then, the cells were fixed and stained with anti-STAT3 antibody and Alexa Fluor Red-conjugated secondary antibody. DAPI was used to visualize the nuclei (original magnification, ×40). (C) ASCs were stimulated with or without Pam3CSK4 (1 μg/ml), poly-IC (10 μg/ml), LPS (1 μg/ml), and R848 (1 μg/ml) for the indicated time periods. The levels of phosphorylated STAT3 (Tyr 705 ) and overall STAT3 were examined in whole cell lysates by immunoblot analysis. Results are representative of at least three independent experiments. agonists such as Pam3CSK4, poly-IC, LPS, or R848. We found that Pam3CSK4, poly-IC, and LPS, but not R848, induced STAT3 phosphorylation (Fig. 4C) . These results suggest that some TLR agonists induce IL-6 secretion by ASCs, and that IL-6 together with sIL-6R activates STAT3.
STAT3 promotes osteogenic differentiation in ASCs
We analyzed the effect of STAT3 using siRNA-mediated gene silencing to examine the role of STAT3 in osteogenic differentiation of ASCs. Under STAT3 knockdown conditions (Fig. 5A) , ASCs showed slightly less ALP activity and calcium accumulation in the extracellular matrix as visualized by ALP (left) and Alizarin Red S (right) staining (Fig. 5B ). STAT3 silencing also consistently decreased osterix, ALP, and osteopontin expression in ASCs (Fig. 5C ). We investigated the effects of STAT3 overexpression on osteogenesis to further confirm the role of STAT3. ASCs were transduced with a retroviral vector encoding constitutively active STAT3 (STAT3C) [31] . Transduced ASCs increased STAT3 expression ( Fig. 5D ), thereby resulting in significantly increased calcium accumulation as indicated by Alizarin Red S staining ( Fig. 5E ). Collectively, these data point to the importance of STAT3 in osteogenesis.
STAT3 inhibitor blocks IL-6-induced osteogenic differentiation of ASCs
We further investigated the effects of pharmacologically inhibiting STAT3 on osteogenesis. Treatment of ASCs with 0.1 μM JSI-124 [32] , a STAT3 inhibitor, effectively blocked osteogenesis induced by IL-6/ sIL-6R (Fig. 6A ). JSI-124 markedly reduced the expression of osteogenic differentiation markers such as osterix, ALP, and osteopontin (Fig. 6B) . Furthermore, the inhibitor reduced STAT3 tyrosine phosphorylation and osterix protein levels, both of which were induced by IL-6/sIL-6R (Fig. 6C ).
STAT3 activates osterix promoter transcription
Based on our observations that IL-6/sIL-6R regulates osteogenesis and also induces osterix transcription, we examined the involvement of STAT3 in osterix induction. We analyzed the putative promoter region of mouse osterix using a program for predicting transcription factor binding sites (Matlnspector software, http://www.genomatix. de/). Indeed, two putative STAT3-binding sites [20] were present in the 5′-flanking region of osterix (Fig. 7A) . The osterix promoter fragment (−2965 to + 80 relative to the transcription start site) linked to a luciferase reporter construct conferred transcriptional activation under IL-6/sIL-6R stimulation (Fig. 7B) . Chromatin immunoprecipitation (ChIP) assays indicated that the binding of STAT3 to the STAT3binding elements located − 2593 and −2606 upstream in the osterix promoter increased during osteogenesis induced by IL-6/sIL-6R ( Fig. 7C ). Taken together, osterix is a direct transcriptional target of STAT3 during IL-6/sIL-6R-induced osteogenesis of ASCs.
Discussion
ASCs represent a readily available and abundant supply of MSCs that can be simply expanded to large numbers in vitro with less cell heterogeneity [33, 34] . Because ASCs differentiate into osteoblasts, Fig. 5 . STAT3 promotes osteogenic differentiation in ASCs. (A) ASCs were transiently transfected with either 10 nM STAT3 siRNA or a nonrelevant siRNA (scrambled). After 48 h transfection, STAT3 expression was determined by immunoblot analysis. GAPDH was used as the loading control. (B) As in (A), except that cells were cultured with osteogenic differentiation medium with or without IL-6 and sIL-6R for 2 wk. ALP activity was determined by staining with NBT/BCIP (left panel) and mineralization was assessed by ARS staining (right panel). (C) As in (B), except that total RNAs were isolated from cells for real time PCR analysis. The mRNA expression levels of osterix, ALP, and osteopontin were normalized against expression of actin mRNA. Experiments were repeated three times, and the results represent average values from triplicate assays. *p b 0.001, significantly different from scramble siRNA transfected control. (D) ASCs were infected with either retrovirus expressing GFP (pMXs) or constitutively active STAT3 (pMXs-STAT3C). After 48 h infection, cell lysates were subjected to immunoblot analysis with anti-STAT3 antibody. (E) Cells infected with pMXs or with pMXs-STAT3C expressing retrovirus were cultured in osteogenic differentiation medium with or without IL-6 and sIL-6R for 2 wk. The extent of mineralized matrix was determined by ARS staining. Results are representative of at least three independent experiments. adipocytes, or chondrocytes in different inductive culture systems [35] , they are considered important for prospective cell-based therapy [36, 37] . In this regard, the characterization of factors and mechanisms that regulate ASC differentiation could allow us to manipulate ASCs for therapeutic use. These studies demonstrate a novel role for TLR signaling through IL-6/STAT3 during osteogenesis and further illustrate the importance of this signaling pathway in the osteogenic differentiation of ASCs.
TLR-mediated signals play prominent roles in initiating immune responses to infection [38] . In mammalian tissues, TLRs are highly expressed by resident immune cells, including dendritic cells, tissue macrophages, and mast cells and to a lesser degree by other cell types including fibroblasts, epithelial cells, and endothelial cells [39] . Upon binding ligands, all known TLRs induce the production of inflammatory cytokines including interferon (IFN)-α, IFN-β, IL-12(p40), TNF-α, IL-6, and IL-1β, which attract innate immune cells and/or promote the initiation and polarization of adaptive immune responses [40] [41] [42] . Besides their role in innate and adaptive immune responses, a recent report suggested that TLRs play an additional role as a sensor for endogenous lipids, mostly through acting on adipose tissue [43, 44] . TLRs appear to have a role in generating non-infectious disease pathogenesis and even in the maintenance of normal mammalian homeostasis [42, 45] . In this context, our results extend TLR biology in mammalian systems beyond its known immune functions and implicate TLR regulation in the fate determination of ASCs.
Our first important finding suggests functional links between TLR expression, IL-6 secretion, and osteoblast differentiation in ASCs. ASCs expressed several TLRs at the mRNA level including TLR1-TLR5. Expression at the mRNA level does not necessarily mean that ASCs have functional receptors. However, our findings indicate the functional status of TLRs in ASCs. Pam3CSK4 (TLR1/2 agonist), poly-IC (TLR3 agonist), LPS (TLR4 agonist), and flagellin (TLR5 agonist) induced osteogenic differentiation and IL-6 secretion, whereas R848 (TLR7/8 agonist) had no effect. The lack of TLR7 and TLR8 expression may account for the unresponsiveness to R848. Our data partially resemble those of Pevsner-Fischer et al. [12] , who found that human MSCs expressed multiple TLRs, except TLR9, and that IL-6 is also secreted from MSCs incubated with Pam3CSK4, peptidoglycan, LPS, and poly-IC, but not with ssRNA40, imiquimod (R837), or CpG.
The second important finding in this study provides mechanistic insights into the roles of IL-6 in ASC osteogenesis. IL-6 is a multifunctional cytokine involved in the regulation of many systems. It plays a major role regulating both inflammatory responses and hematopoiesis [46] [47] [48] . We have shown that ASCs do not express membrane-bound IL-6R at a detectable level and fail to respond to IL-6 alone, which was consistent with the finding that MSCs lack IL-6R expression [49] . However, our results showed that a combination of IL-6 and sIL-6R enhanced osteogenesis. It seems likely that ASCs that express no or little membrane-bound IL-6R are able to respond to the IL-6/sIL-6R complex as long as they express gp130. Notably, all cells in the body express gp130 [17, 50] , and circulating levels of sIL-6R are maintained at substantially high levels in normal individuals (approximately 75 ng/ml) [17, 51] . Additionally, IL-6 concentrations produced by TLR agonists from ASCs were 2-4 ng/ml, which were lower than the IL-6 concentration used in this study to stimulate ASCs in vitro. Plasma IL-6 levels are barely detectable in healthy subjects (2-6 pg/ml) [51] ; thus, the levels of IL-6 induced by TLR agonists in ASCs are roughly 1000 times higher than those of normal IL-6 plasma levels.
We found that TLR agonists such as Pam3CSK4, poly-IC, and LPS, but not R848, as well as the exogenous addition of IL-6/sIL-6R to osteogenic induction media induced STAT3 phosphorylation in ASCs. We also observed that STAT3 phosphorylation showed a plateau of maximum stimulation within 5-30 min and decreased thereafter until 4 h. Given this time course, it is most likely that IL-6 secreted by ASCs in response to TLR agonists activates STAT3 together with sIL-6R, which has been observed in various body fluids [52, 53] . It is likely that STAT3 activation initiates the expression of factor(s) known to promote osteogenic differentiation. In support of this hypothesis, we clearly demonstrated that IL-6/sIL-6R-induced STAT3 phosphorylation is critical for the induction of osterix, which is an essential early stage transcription factor for osteoblast differentiation [30] . Indeed, the ChIP assays showed that IL-6/sIL-6R induced binding of STAT3 to sequences in the osterix promoter within ASCs. IL-6 is widely recognized as a potent stimulator of osteoclastdriven bone resorption in the context of chronic inflammation and estrogen deficiency [54] . Estrogen depletion causes significant bone loss together with increased bone turnover rates in wild type animals, but ovariectomy fails to induce any changes in either bone mass or bone remodeling rates in the IL-6-deficient mice [55] , suggesting that IL-6 may play a role in menopausal osteoporosis. Given the key role of IL-6 in inflammatory diseases such as rheumatoid arthritis, it is important to note that therapeutic blockade of IL-6 has begun to offer therapeutic strategies for treating rheumatoid arthritis. For example, Tocilizumab, a humanized monoclonal antibody against the IL-6R, is used for the treatment of moderate to severe rheumatoid arthritis in adults [56] .
The origin of MSCs or ASCs may determine their fate and functional characteristics [57] . Furthermore, the exact functions of MSCs or ASCs within tissues remain largely unknown, but they appear to perform distinct roles in specific tissues where they reside. In this context, MSCs or ASCs may differentiate into specialized cells upon receiving TLR signals during tissue inflammation or injury and play a pivotal role in tissue repair and/or in control of inflammation.
In summary, although some TLRs play a role in MSC functions, the molecular mechanisms through which TLR signals are transduced to produce cytokines, which then promotes osteogenic differentiation, have remained obscure. We have shown here that some TLR agonists are capable of utilizing the innate immune TLR receptors to induce IL-6 expression in ASCs. Moreover, IL-6/STAT3 signaling appears to be required to induce the expression of osterix, which is an essential transcription factor for osteogenic differentiation. (B) ASCs were transiently transfected with reporter constructs containing mouse osterix promoter from −2965 to +80 relative to the transcription start site. One day after, cells were cultured in osteogenic differentiation medium with or without 50 ng/ml IL-6 and 50 ng/ml sIL-6R for 3 d followed by luciferase assay. Data were obtained from three independent transfections and presented as the fold induction over the activity of pGL3-basic without IL-6/sIL-6R treatment (mean ± S.D.). *p b 0.01, significantly different from IL-6/ sIL-6R untreated control. (C) ChIP analysis of STAT3 binding to the osterix promoter. ASCs were treated with or without 50 ng/ml IL-6 and 50 ng/ml sIL-6R for 1 h to induce nuclear STAT3 translocation. ChIP assays were performed on cell lysates by using an STAT3 antibody followed by PCR analysis. Input corresponded to PCR containing 1% of the total amount of chromatin used in the immunoprecipitation reactions. Results are representative of three independent immunoprecipitations.
